Gestational Trophoblastic Tumours: An Update for 2014
Gestational trophoblastic disease describes a variety of pregnancy-related diseases including the premalignant conditions of a partial and complete hydatidiform mole and the malignant disorders of invasive mole, choriocarcinoma and the rare placental-site trophoblastic tumour and epithelioid trophoblastic tumour. The availability of a highly sensitive tumour marker in the form of human chorionic gonadotrophin, the chemosensitive character of the disease with effective treatment strategies and centralization of care of a rare group of diseases has resulted in excellent survival rates, which can exceed 98 %. This review gives a general overview of gestational trophoblastic disease, the most recent insights in aetiology and pathology and a summary of the different management strategies.
KeywordsGestational trophoblastic disease Molar pregnancy Choriocarcinoma Trophoblastic tumours Pregnancy-related diseases Gynaecological cancers Oncology Choriocarcinoma Trophoblastic tumours Pregnancy-related diseases Gynaecologic cancers
Compliance with Ethics Guidelines
Conflict of Interest
Fieke E. M. Froeling and Michael J. Seckl declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.••Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi39–50. This is a recently published European Society for Medical Oncology guideline which gives a clear general overview of GTD.PubMedCrossRefGoogle Scholar
- 19.National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. Available from: http://www.nice.org.uk/Guidance/cg154.
- 23.Sebire NJ, Foskett M, Short D, Savage P, Stewart W, Thomson M, et al. Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG. 2007;114(6):760–2.PubMedCrossRefGoogle Scholar
- 24.Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A Prog Rep J Reprod Med. 2002;47(6):445–50.Google Scholar
- 25.••Agarwal R, Teoh S, Short D, Harvey R, Savage PM, Seckl MJ. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012;379(9811):130–5. This is retrospective study of 76 women with persistently elevated hCG levels more than 6 months after evacuation showed that continued observation is safe as long as the hCG level is decreasing, resulting in a change in the widely accepted criteria to initiate treatment.PubMedCrossRefPubMedCentralGoogle Scholar
- 32.•Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125(3):576–9. This is a retrospective study that showed a reduced relapse rate with three consolidation cycles compared with two cycles of methotrexate for treatment of low-risk GTN. On the basis of this study and extensive experience in the UK, treatment with three consolidation cycles is recommended for low-risk disease.PubMedCrossRefGoogle Scholar
- 34.•Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280–6. This retrospective analysis of 438 patients who received EMA/CO for treatment of high-risk GTN demonstrated a clear benefit of starting treatment with low-dose EP in patients with a large disease burden. Induction therapy with low-dose EP should therefore routinely be considered in the treatment of very high-risk GTN.PubMedCrossRefGoogle Scholar
- 38.Seckl MJ, Newlands ES. Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. http://www.isstd.org/isstd/book.html. 2009. p. 335–65.
- 43.The ISSTD Global Placental Site Trophoblastic Tumour Database. International Society of the Study of Trophoblastic Diseases. https://pstt.shef.ac.uk.
- 50.Savage PM, Cooke R, O’Nions J, Krell J, Kwan A, Michelle C, et al. The effects of single agent and combination chemotherapy for gestational trophoblastic tumours on risks of second malignancy and early menopause. J Clin Oncol. 2014; in press.Google Scholar